Commentary: The ALLHAT Study: implications for the management of resistant hypertension.
作者信息
Singer Gregory M, Setaro John F
机构信息
Section of Cardiovascular Medicine, Yale University School of Medicine, 333 Cedar Street, Box 208017, New Haven, CT 06520-8017, USA.
出版信息
J Clin Hypertens (Greenwich). 2005 Jan;7(1):31-2. doi: 10.1111/j.1524-6175.2005.04302.x.
Abstract
摘要
相似文献
1
Commentary: The ALLHAT Study: implications for the management of resistant hypertension.
J Clin Hypertens (Greenwich). 2005 Jan;7(1):31-2. doi: 10.1111/j.1524-6175.2005.04302.x.
2
The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: a connection with uric acid?
Cardiovasc Drugs Ther. 2002 Dec;16(6):485-7. doi: 10.1023/a:1023090823731.
3
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.
Hypertension. 2003 May;41(5):1006-9. doi: 10.1161/01.HYP.0000070905.09395.F6. Epub 2003 Apr 14.
4
ALLHAT and beyond.
Am J Hypertens. 2003 Jun;16(6):512-4. doi: 10.1016/s0895-7061(03)00856-2.
5
ALLHAT: setting the record straight.
Ann Intern Med. 2004 Jul 6;141(1):39-46. doi: 10.7326/0003-4819-141-1-200407060-00013.
6
Comments on the renal aspects of the ALLHAT study.
J Hypertens. 2003 Feb;21(2):235-6. doi: 10.1097/00004872-200302000-00005.
7
Never mind the quality, feel the width--ALLHAT revisited.
Blood Press. 2004;13(6):330-4. doi: 10.1080/08037050410004576.
8
[ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
Nihon Rinsho. 2001 Mar;59 Suppl 3:393-7.
9
ALLHAT, or the soft science of the secondary end point.
Ann Intern Med. 2004 Jul 6;141(1):77. doi: 10.7326/0003-4819-141-1-200407060-00023.
10
ALLHAT in perspective: implications to clinical practice and clinical trials.
Med J Malaysia. 2005 Jun;60(2):239-45.
本文引用的文献
1
Resistant hypertension revisited: a comparison of two university-based cohorts.
Am J Hypertens. 2005 May;18(5 Pt 1):619-26. doi: 10.1016/j.amjhyper.2004.11.021.
2
Continued importance of diuretics and beta-adrenergic blockers in the management of hypertension.
Med Clin North Am. 2004 Jan;88(1):167-87. doi: 10.1016/s0025-7125(03)00121-4.
3
Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.
JAMA. 2003 Jul 9;290(2):199-206. doi: 10.1001/jama.290.2.199.
4
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.
BMJ. 2003 Jun 28;326(7404):1427. doi: 10.1136/bmj.326.7404.1427.
5
Results of ALLHAT: is this the final answer regarding initial antihypertensive drug therapy?
Arch Intern Med. 2003 Jun 9;163(11):1269-73. doi: 10.1001/archinte.163.11.1269.
6
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
JAMA. 2003 May 21;289(19):2560-72. doi: 10.1001/jama.289.19.2560. Epub 2003 May 14.
7
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
JAMA. 2003;289(16):2073-82. doi: 10.1001/jama.289.16.2073.
8
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.
JAMA. 2003 Jan 1;289(1):76-9. doi: 10.1001/jama.289.1.76.
9
Treatment of hypertension in adults with diabetes.
Diabetes Care. 2003 Jan;26 Suppl 1:S80-2. doi: 10.2337/diacare.26.2007.s80.
10
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981.
Zotero 插件